Sight Sciences Q2 Revenue Jumps 20% to $23.4M, Loss Narrows; Alcon Appeal Looms
SGHT sits 65% above its 52-week low of $3.19 on elevated volume (2.3× avg).
Summary
Sight Sciences reported Q2 revenue of $23.4M (+20% YoY), beating estimates, and a sharply narrower net loss. The Alcon patent win was finalized at $55.4M but is under appeal.
Key Events · Earnings and Guidance · SGHT
-
Q2 Revenue Beats, Loss Narrows
Revenue rose 20% to $23.4M, exceeding the $21.68M consensus. Net loss improved to $4.4M from $11.9M in Q2 2025, driven by higher sales and gross margin expansion to 91.4%.
-
Alcon Litigation: $55.4M Judgment Under Appeal
The court entered a final judgment of $55.4M in damages plus a 10% royalty on Hydrus sales, but Alcon filed an appeal. The outcome remains uncertain, and two patent reexaminations are still pending.
-
Cash Burn Continues, Runway Confirmed
Cash and equivalents fell to $79.8M from $92.0M at year-end 2025. Management believes existing liquidity is sufficient for at least the next 12 months.
-
Dry Eye Segment Revenue Surges
Interventional Dry Eye revenue jumped to $2.7M from $0.3M a year ago, driven by higher SmartLid volumes and improved reimbursement coverage.
Analysis · SGHT · Industrial Applications And Services
A strong second quarter saw revenue climb 20% to $23.4 million, topping the $21.68 million consensus, while the net loss shrank to $4.4 million from $11.9 million a year ago. Gross margin surged to 91.4%, aided by tariff refunds and higher selling prices. Separately, the company disclosed that a court entered a $55.4 million final judgment in its patent case against Alcon, plus a 10% ongoing royalty, but Alcon has appealed, leaving the award uncertain. Cash declined to $79.8 million, though management says it is sufficient for at least 12 months. The results confirm accelerating momentum in both glaucoma and dry eye segments, yet the appeal and cash burn remain key risks.
At the time of this filing, SGHT was trading at $5.25 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $302M. The 52-week trading range was $3.19 to $9.24. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.